Immunity to Immunotherapy in Cancer
Mechanisms and Limitations
- 1st Edition - June 1, 2026
- Latest edition
- Editors: Mukesh Nandave, Deepa Mandlik
- Language: English
Immunity to Immunotherapy in Cancer: Mechanisms and Limitations explores the intricate interplay between cancer therapy and the immune system, addressing why some patients do not… Read more
Immunity to Immunotherapy in Cancer: Mechanisms and Limitations explores the intricate interplay between cancer therapy and the immune system, addressing why some patients do not respond to immunotherapy and the scientific solutions in development. The book examines molecular strategies of immune evasion within the tumour microenvironment, providing insights into factors like tumour heterogeneity and immune checkpoint mechanisms that contribute to resistance. Highlighting promising approaches such as combination therapies, personalized medicine, and novel immunotherapeutic agents, it aims to enhance patient outcomes and advance cancer immunotherapy. Designed as a comprehensive guide for professionals and researchers, this textbook offers an overview of the latest scientific discoveries and practical applications in cancer therapy. It serves as an invaluable resource for scientists, doctors, academicians, and students, presenting a path toward more effective, non-toxic, and customized cancer treatments. This book is essential for anyone interested in the future of cancer therapy.
- Provides an in-depth examination of the molecular strategies of immune evasion and the tumour microenvironment, offering critical insights into why some patients do not respond to immunotherapy
- Bridges the gap between current research and practical therapeutic applications in cancer immunotherapy
- Highlights the latest advancements in cancer therapy, discussing cutting-edge strategies such as combination therapies, personalized medicine, and novel immunotherapeutic agents
Researchers in the field of immunology, oncology and cancer research
Part A: Cancer Immunity
1. Introduction to Immunity in Cancer
2. Role of Innate Immunity in Cancer Immunology
3. Role of Dendritic Cells in Cancer Immunology
4. Role of Natural Killer Cells in Cancer Immunology
5. Role of B-Cells in Tumor Immunity
6. Role of CD4+ T-Cells in Cancer Immunology
7. Role of Regulatory T-Cells and Th17 Cells in Tumor Microenvironment
8. Role of Monocytes, Macrophages, and Polymorphonuclear Cells in Cancer Immunology
9. Role of Cytokines in Cancer Immunology
10. Role of Chemokines and Chemokine Receptors in Cancer Immunology
11. Role of the Inflammasome in Cancer Immunology
12. Current Advanced Immunological Tools and Databases in Tumor Immunity
13. Tumor Heterogeneity and Therapeutic Resistance
Part B: Cancer Immunotherapy
14. Cancer Immunotherapy: Pros, Cons, and Beyond
15. Role of Monoclonal Antibody, Immune Checkpoint Inhibitors, and Programmed Death Ligand 1 in Cancer Immunotherapy
16. Role of Chimeric Antigen Receptor-T Cell in Cancer Immunotherapy
17. Role of Small Molecule-Based Drugs in Cancer Immunotherapy
18. Role of Adoptive Cell Therapy in Cancer Immunotherapy
19. Role of Cancer Vaccines in Cancer Immunotherapy
20. Role of Radiotherapy/Chemotherapy in Cancer Immunotherapy
1. Introduction to Immunity in Cancer
2. Role of Innate Immunity in Cancer Immunology
3. Role of Dendritic Cells in Cancer Immunology
4. Role of Natural Killer Cells in Cancer Immunology
5. Role of B-Cells in Tumor Immunity
6. Role of CD4+ T-Cells in Cancer Immunology
7. Role of Regulatory T-Cells and Th17 Cells in Tumor Microenvironment
8. Role of Monocytes, Macrophages, and Polymorphonuclear Cells in Cancer Immunology
9. Role of Cytokines in Cancer Immunology
10. Role of Chemokines and Chemokine Receptors in Cancer Immunology
11. Role of the Inflammasome in Cancer Immunology
12. Current Advanced Immunological Tools and Databases in Tumor Immunity
13. Tumor Heterogeneity and Therapeutic Resistance
Part B: Cancer Immunotherapy
14. Cancer Immunotherapy: Pros, Cons, and Beyond
15. Role of Monoclonal Antibody, Immune Checkpoint Inhibitors, and Programmed Death Ligand 1 in Cancer Immunotherapy
16. Role of Chimeric Antigen Receptor-T Cell in Cancer Immunotherapy
17. Role of Small Molecule-Based Drugs in Cancer Immunotherapy
18. Role of Adoptive Cell Therapy in Cancer Immunotherapy
19. Role of Cancer Vaccines in Cancer Immunotherapy
20. Role of Radiotherapy/Chemotherapy in Cancer Immunotherapy
- Edition: 1
- Latest edition
- Published: June 1, 2026
- Language: English
MN
Mukesh Nandave
Experienced Associate Professor in Pharmacology with a demonstrated history of working in national and international organisations. Strong professional skilled in Pharmaceutical Research, Molecular Biology, Inflammation, and cardiovascular and metabolic diseases.
Affiliations and expertise
Delhi Pharmaceutical Sciences and Research University, IndiaDM
Deepa Mandlik
Dr. Satish K. Mandlik currently is working as an Associate Professor at Bharati Vidyapeeth (Deemed to be University)’s Poona College of Pharmacy, Pune. He has 16 years teaching and research experience of 11 years. He holds fourth rank in University of Pune for B. Pharmacy and first rank in Goa University for M. Pharmacy (QA). He has published more than 35 research publications in national and international repute journals. His Publications Metrics/ Statistics includes H index: 12, Total Citations: 710, Cumulative Impact factor: 40+ He has authored 5+ Pharmaceutical books, 7 International book Chapters. He is a recognized PhD Guide and currently guiding 3 PhD scholars. He has guided 20+ PG (M. Pharm) students. He is life member of APTI and member of CRS-Indian Chapter. He has great aptitude for research areas like nanotechnology, drug targeting, quality by design, design of experiments and optimization techniques.
Affiliations and expertise
Bharti Vidyapeeth Deemed University, India